Abstract PR01: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry
Amanda L. Rinkenbaugh(University of North Carolina at Chapel Hill), Helen Piwnica‐Worms(Centre for Cancer Biology), Gloria V. Echeverria(Baylor College of Medicine), Vidya C. Sinha(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Jiansu Shao(The University of Texas MD Anderson Cancer Center), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991